IDH2 and acute myeloid leukemia: However, the phase III randomized trial of IDH2 inhibitor in R/R AML failed to show an improvement in overall survival compared to conventional regimens (p = 0.2), despite a significant improvement in event-free survival likely due to the substantial number of patients who dropped out from the non-enasidenib arm and received enasidenib as a subsequent therapy [60].